Please type a plus sign (+) inside this box \rightarrow +

PTO/SB/08A (08-00)

Substitute for F	orm 1449A/PTC)			Complete if Known			
INFORMATION STATEMENT	ON DISCLOSU BY APPLICA	JRE NT		Application Number	09/700,329			
NAR 3	Euse as many	sheets as 1	necessary)	Filing Date	February 8, 2001			
(3	o soon Si			First Named Inventor	Philip C. Gevas et al			
MAN 3				Group Art Unit	1632			
MAR 3 0 2001 SE				Examiner Name				
Sheet	1 of 2 Attorney Docket Number ACG2AUSA			ACG2AUSA				

U.S. PATENT DOCUMENTS									
Examiner Initials	Cite No.1	U.S. Patent Document		Name of Patentee or Applicant of	Date of Publication of	Pages, Columns, Lines, Where Relevant			
	No.	Number	Kind Code ² (if known)	Cited Document	Cited document MM-DD-YYYY	Passages or Relevant Figures Appear			
my	AA	5,023,077	В1	Philip Gevas	06/11/1991				
	AB	5,468,494	В1	Philip Gevas	11/21/1995				
	AC	5,607,676	В1	Philip Gevas	03/04/1997				
	AD	5,609,870	В1	Philip Gevas	03/11/1997				
	AE	5,622,702	B1	Philip Gevas	04/22/1997				
pars	AF	5,785,970	B1	Philip Gevas	07/28/1998				

FOREIGN PATENT DOCUMENTS									
Examiner Initials*	Cite No.1				Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document	Pages, Columns, Lines, Where Relevant	T	
		Office ³	Number ⁴	Kind Code ⁵ (if known)		MM-DD-YYYY	Passages or Relevant Figures Appear		
_									

Examiner Signature	Ulms	Date Considered	04/01/03

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-leves code (WIBO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document by thind of decument by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if Emperor and a standard stand

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for	r Form 1449A/	PTO		Complete if Known			
	TION DISCL			Application Number	09/700,329		
61F	E _(ust ca)	any sheets as nec	essary)	Filing Date February 8, 2001			
MAR	3 0 5001 PS	:		First Named Inventor	Philip C. Gevas et al		
P.	8 P	<i>(</i>		Group Art Unit	1632		
MAR 3 0 too.				Examiner Name			
Sheet 2 of				Attorney Docket Number	ACG2AUSA		

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiners Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
my	AR	S. WATSON et al, "Anti-Gastrin Antibodies Raised by Gastrimmune Inhibit Growth of the Human Colorectal Tumour AP5", Int. J. Cancer, 61:233-240 (1995)	
	AS	S. WATSON et al, "Gastrimmune Raises Antibodies that Neutralize Amidated and Glycine-extended Gastrin-17 and Inhibit the Growth of Colon Cancer", Cancer Research, 56:880-885 (February 15, 1996)	
	AT	M. THORNDYKE et al, "Identification and Localization of Material with Gastrin-like Immunoreactivity in the Neural Ganglion of a Protochordate, <i>Ciona intestinalis</i> ", Regulatory Peptides, 16:269-279 (1986)	
	AU	S. BUDAVARI et al, The Merck Index (11th ed.), Rahway, New Jersey, Merck & Co., p. 1082 (1989)	
my	AV	P. GEVAS et al, "Method for the Treatment of Gastroesophageal Reflux Disease", U. S. Patent Application No. 09/700,378, filed March 1, 2001	
		15 ²	
		O. HINIO ROY	

Examiner Signature

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in Oxformance and not considered Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.

#15

Please type a plus sign (+) inside this box \rightarrow

PTO/SB/08B (08-00)

Substitute f	for Form 1449A/PT	O		Complete if Known		
	ATION DISCLOS			Application Number	09/700,329	
	(use as many		s recessary)	Filing Date	February 28, 2001	
			C ANN 1 8 AUG.	First Named Inventor	Philip C. Gevas et al RECEIVED	
			ATTATEMENT S	Group Art Unit	1632 JUN 2 4 2002	
			ENT & TRADE	Examiner Name	M. Borin	
Sheet	1	of	1	Attorney Docket Number	ACG2AUSA TECH CENTER 1600/290	

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiners Initials* ES ES ET		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.					
		S. WATSON et al, "Pre-Clinical Evaluation of the Gastrimmune Immunogen Alone and in Combination with 5-Fluorouracil/Leucovorin in a Rat Colorectal Cancer Model", Int. J. Cancer, 75:873-877 (1998)					
		M. SUMII et al, "Regulation of Antral Peptides by Administration of Omeprazole to Healthy Men", The American Journal of Gastroenterology, 89(11):2033-2037 (November, 1994)					
	EU	R. MCCLOY et al, "Pathophysiological Effects of Long-Term Acid Suppression in Man", Digestive Diseases and Sciences, 40(2):96S-120S (February, 1995 Supplement)					
ru, EV		J. FRESTON et al, "Long-Term Acid Control and Proton Pump Inhibitors: Interactions and Safety Issues in Perspective", The American Journal of Gastroenterology, 92(4):51S-57S (April, 1997 Supplement)					

			· / /	
Examiner	110	Date	gy los los	j .
Signature	Mons	Considered		ļ.

^{*} EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation designation number. ²Applicant is to place a check mark here if English language Translation is attached.